ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

MLA

Jeffrey M. Holzbeierlein, et al. “ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.” Journal of Clinical Oncology, vol. 37, Nov. 2019, pp. 2974–86. EBSCOhost, https://doi.org/10.1200/jco.19.00799.

APA

Jeffrey M. Holzbeierlein, Taro Iguchi, Russell Z. Szmulewitz, Benoit Baron, Andrew J. Armstrong, Neal D. Shore, Daniel P. Petrylak, Boris Alekseev, Jennifer Sugg, Arnulf Stenzl, Brad Rosbrook, Arnauld Villers, Arun Azad, Antonio Alcaraz, & Lucy F. Chen. (2019). ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 37, 2974–2986. https://doi.org/10.1200/jco.19.00799

Chicago

Jeffrey M. Holzbeierlein, Taro Iguchi, Russell Z. Szmulewitz, Benoit Baron, Andrew J. Armstrong, Neal D. Shore, Daniel P. Petrylak, et al. 2019. “ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.” Journal of Clinical Oncology 37 (November): 2974–86. doi:10.1200/jco.19.00799.